

PDL BioPharma Inc (PDLI) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/P896F2CCC42EN.html>

Date: May 2020

Pages: 54

Price: US\$ 125.00 (Single User License)

ID: P896F2CCC42EN

Abstracts

PDL BioPharma Inc (PDLI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

PDL BioPharma Inc (PDL) formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets that include Queen et al. patents and license agreements with various pharmaceutical and biotechnology companies, and royalty and other acquired assets. It offers financing solutions and non-dilutive growth capital to public and private healthcare companies. PDL provides companies, academic institutions and inventors with an immediate financial monetization of royalty streams for acquiring new income generating assets. The company also carries out the humanization of monoclonal antibodies for facilitating the discovery of targeted treatments for cancer and other immunologic diseases. PDL is headquartered in Incline Village, Nevada, the US.

PDL BioPharma Inc Key Recent Developments

Mar 11,2020: PDL BioPharma reports 2019 fourth quarter and full year financial results and announces plan to dissolve the company by year-end 2020

Mar 09,2020: PDL BioPharma announces appointment of Edward A. Imbrogno as vice president and chief financial officer

Feb 28,2020: PDL BioPharma Enters into cooperation agreement with Engine Capital

Dec 23,2019: PDL BioPharma: Departure of directors or certain officers; election of

directors; appointment of certain officers; compensatory arrangements of certain officers.

Dec 09,2019: PDL BioPharma announces completion of strategic review process

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

PDL BioPharma Inc - Key Facts
PDL BioPharma Inc - Key Employees
PDL BioPharma Inc - Key Employee Biographies
PDL BioPharma Inc - Major Products and Services
PDL BioPharma Inc - History
PDL BioPharma Inc - Company Statement
PDL BioPharma Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
PDL BioPharma Inc - Business Description
Business Segment: Income Generating Assets
Overview
Performance
Business Segment: Medical Devices
Overview
Performance
Business Segment: Pharmaceutical
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: United States
Performance
PDL BioPharma Inc - Corporate Strategy
PDL BioPharma Inc - SWOT Analysis
SWOT Analysis - Overview
PDL BioPharma Inc - Strengths
PDL BioPharma Inc - Weaknesses
PDL BioPharma Inc - Opportunities

PDL BioPharma Inc - Threats
PDL BioPharma Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
PDL BioPharma Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 11, 2020: PDL BioPharma reports 2019 fourth quarter and full year financial results and announces plan to dissolve the company by year-end 2020
Mar 09, 2020: PDL BioPharma announces appointment of Edward A. Imbrogno as vice president and chief financial officer
Feb 28, 2020: PDL BioPharma Enters into cooperation agreement with Engine Capital
Dec 23, 2019: PDL BioPharma: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers.
Dec 09, 2019: PDL BioPharma announces completion of strategic review process
Nov 06, 2019: PDL BioPharma reports 2019 third quarter financial results
Sep 11, 2019: PDL BioPharma announces favorable decision in Wellstat Diagnostics litigation
Aug 07, 2019: PDL BioPharma reports 2019 second quarter financial results
Jun 25, 2019: PDL BioPharma announces departure of CFO
Jun 24, 2019: Natasha A. Hernday elected to PDL BioPharma's board of directors

SECTION 6 – APPENDIX

Methodology

[Ratio Definitions](#)
[About GlobalData](#)
[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

PDL BioPharma Inc, Key Facts
PDL BioPharma Inc, Key Employees
PDL BioPharma Inc, Key Employee Biographies
PDL BioPharma Inc, History
PDL BioPharma Inc, Subsidiaries
PDL BioPharma Inc, Key Competitors
PDL BioPharma Inc, Ratios based on current share price
PDL BioPharma Inc, Annual Ratios
PDL BioPharma Inc, Annual Ratios (Cont...1)
PDL BioPharma Inc, Annual Ratios (Cont...2)
PDL BioPharma Inc, Interim Ratios
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
PDL BioPharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

PDL BioPharma Inc, Performance Chart (2015 - 2019)

PDL BioPharma Inc, Ratio Charts

PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

Seattle Genetics Inc

Ocera Therapeutics Inc

Gilead Sciences Inc

Genentech Inc

Dyax Corp

Audentes Therapeutics Inc

I would like to order

Product name: PDL BioPharma Inc (PDLI) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/P896F2CCC42EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P896F2CCC42EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970